PEPTIDE

BPC-157

Pentadecapeptide derived from human gastric juice; modulates VEGF and growth-hormone receptor expression in injured tissue.

BIOGATE · GREEN | POSTERIOR 88.1% | MW 1419.5 | 15AA

SEQUENCE

GEPPPGKPADDAGLV

Modifications: acetyl-N-terminus

PDA-V1 chain of custody

Outer hash

c34cc1dbc24cc048c54cc501c44cc36ec74cc827c64cc694c94ccb4

Merkle root

00-c1b6cc01c1b85f02c1b9f203c1bb85fcc1b080fdc1b213fec1b3a6ffc1b539

Inputs

5839275-b573925c85a392a81593928ee5c392da75b392c145e3930cd5d392f

TEE attestation

1-c6655361d6656c91a6652101b6653a320665b8221665d151e66585c1f6659ef

Living Outcome Oracle

± =33.8 ² =4.6 **P(success) = 88.1%**

95% CI [76.1%, 100.0%]

Suggested protocol

Post-Surgical Soft-Tissue Recovery

GRADE B

Accelerated tendon and connective-tissue recovery following elective orthopedic surgery

DOSE PROTOCOL

BPC-157 250 µg SC bid + TB-500 2 mg SC twice weekly

Cycle: 4 weeks on / 2 weeks off · Duration: 12 weeks (2 cycles)

MONITORING ENDPOINTS

- VAS pain score
- ROM (goniometric)
- CRP
- WHOOP recovery score 7-day rolling

Seven-rule export gate

7 / 7 rules satisfied · audience: clinician · Dose protocol, contraindications, monitoring endpoints, jurisdiction gates

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

Citations

GRADE B

2013 · Curr Pharm Des

Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease

Sikiric P et al.

PMID 23316008

GRADE B

2010 · J Orthop Res

Achilles tendon-to-bone reattachment: BPC 157 acceleration

Krivic A et al.

PMID 21030672